Bioneer Corporation
Financials
Valuation Metrics
Bioneer Corporation's Market Cap is ₩1760B. At end of 2025 it was ₩3291B. Ranked #895 of 2,436 in KR market (top 37%), #421 of 1,649 on KOSDAQ (top 26%), #99 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 42%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 176.03B KRW | KR#895/2,436 Sec#99/234 |
| Revenue | 338.01B KRW | KR#773/2,436 Sec#35/234 |
| Net Income | -2.23B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 368.98B KRW | KR#900/2,436 Sec#54/234 |
| Net Assets | 218.22B KRW | KR#881/2,436 Sec#61/234 |
| Employees | 392 | KR#620/2,436 Sec#54/234 |
| Value | ||
| P/B | 0.81x | KR#1,292/2,436 Sec#77/234 |
| P/S | 0.52x | KR#969/2,436 Sec#42/234 |
| EV/EBITDA | 21.88x | KR#1,058/2,436 Sec#62/234 |
| FCF Yield | 2.01% | KR#1,071/2,436 Sec#71/234 |
| Profitability | ||
| ROE | -1.02% | KR#1,565/2,436 Sec#108/234 |
| ROA | -0.60% | KR#1,565/2,436 Sec#109/234 |
| Op. Margin | 3.06% | KR#1,209/2,436 Sec#93/234 |
| Revenue Growth | 10.69% | KR#896/2,436 Sec#80/234 |
| Earnings Growth | -347.47% | KR#1,587/2,436 Sec#105/234 |
| Financial Health | ||
| Debt Ratio | 169.08% | KR#1,434/2,436 Sec#164/234 |
| Total Debt | 104.91B KRW | KR#694/2,436 Sec#41/234 |
| FCF | 3.55B KRW | KR#986/2,436 Sec#71/234 |
| Cash | 54.37B KRW | KR#708/2,436 Sec#41/234 |
| Current Ratio | 2.04x | KR#926/2,436 Sec#107/234 |
| Net Debt/EBITDA | 4.88x | KR#1,082/2,436 Sec#83/234 |
| Dividend | ||
| Div. Yield | 2.74% | KR#711/2,436 Sec#39/234 |
| Performance | ||
| 1Y Return | -53.89% | KR#2,144/2,436 Sec#202/234 |
| 1M Return | 3.65% | KR#562/2,436 Sec#48/234 |
| From 52W High | -57.85% | KR#1,606/2,436 Sec#136/234 |
| 1Y MDD | -64.97% | KR#1,694/2,436 Sec#144/234 |
| Trading | ||
| Volume | 87,118 shares | KR#1,013/2,436 Sec#98/234 |
| Foreign Own. | 7.81% | KR#585/2,436 Sec#55/234 |
| Per Share | ||
| EPS | -226 KRW | KR—/2,436 Sec—/234 |
| BPS | 7,960 KRW | KR#1,075/2,436 Sec#77/234 |
Company Info
Established in 1992 as the first researcher startup from the Korea Research Institute of Bioscience and Biotechnology, the company is a genetic engineering specialist listed on KOSDAQ in 2005. It operates diverse bio-healthcare businesses, including life science research equipment, reagents, molecular diagnostics, and synthetic biology. The company is developing a next-generation molecular diagnostics platform and a SAMiRNA new drug development platform to pursue global market entry. It also reinvests in research and development and expands its business portfolio through technological innovation. Bioneer is headquartered in Yuseong-gu, Daejeon.